According to Roche's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 15.4259. At the end of 2022 the company had a P/E ratio of 19.1.
Year | P/E ratio | Change |
---|---|---|
2022 | 19.1 | -18.23% |
2021 | 23.4 | 29.87% |
2020 | 18.0 | -15.58% |
2019 | 21.3 | -0.99% |
2018 | 21.5 | -17.87% |
2017 | 26.2 | 12.51% |
2016 | 23.3 | -19.56% |
2015 | 28.9 | 7.95% |
2014 | 26.8 | 44.51% |
2013 | 18.6 | 11.26% |
2012 | 16.7 | 11.32% |
2011 | 15.0 | 7.43% |
2010 | 13.9 | -37.01% |
2009 | 22.1 | 23.37% |
2008 | 17.9 | -16.64% |
2007 | 21.5 | -32.25% |
2006 | 31.8 | -22.32% |
2005 | 40.9 | 94.98% |
2004 | 21.0 | -54.94% |
2003 | 46.6 | -336.57% |
2002 | -19.7 | -174.53% |
2001 | 26.4 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 11.0 | -28.99% | ๐บ๐ธ USA |
Novartis NVS | 27.5 | 77.99% | ๐จ๐ญ Switzerland |
Pfizer PFE | 15.5 | 0.79% | ๐บ๐ธ USA |
Abbott Laboratories ABT | 35.3 | 128.73% | ๐บ๐ธ USA |
Amgen AMGN | 22.2 | 44.18% | ๐บ๐ธ USA |
Sanofi SNY | 15.4 | -0.49% | ๐ซ๐ท France |
Becton Dickinson BDX | 42.6 | 176.38% | ๐บ๐ธ USA |
Merck MRK | 71.8 | 365.75% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 12.8 | -16.89% | ๐ฌ๐ง UK |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.